Q-omics provides the consensus-scored MTND6P4 profile across patient tissues and cancer cell-line models. MTND6P4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MTND6P4 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, MTND6P4 RNA expression shows 14,163 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, HNSC, and ACC as cancer lineages where MTND6P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND6P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND6P4 survival associations across molecular data types. MTND6P4 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND6P4 RNA expression–survival associations across cancer types. High MTND6P4 expression shows favorable associations in BLCA, KIRP, SKCM, THCA, LGG and ACC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify BLCA as the clearest survival context for MTND6P4 RNA expression.
This table summarizes MTND6P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MTND6P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND6P4 shows lower tumor expression in HNSC, LUAD, LUSC, UCEC and BRCA and higher tumor expression in KICH. The HNSC box plot shows higher MTND6P4 RNA expression in normal versus tumor tissue (log2 FC = −0.906, t-test p < 0.001).
This table shows molecular features associated with MTND6P4 in patient tissues and cancer cell lines. In patient samples, MTND6P4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
